Price movement over the last 24 hours
ADMA Biologics Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $40.13. The key difference: YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | QDTY | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $20.38 | $46.71 |
52-Week Low | $7.60 | $36.57 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
QDTY trades at $41.16, up 1.66% today, but technical indicators signal a bearish trend with moving averages and overall signals pointing lower. The stock exhibits weekly dividend distributions, with recent payouts ranging from $0.22 to $0.32. Support and resistance levels are clustered near the current price, indicating potential volatility. Recent news focuses heavily on dividend announcements from YieldMax ETFs, with minimal coverage of broader business performance or financial results.
The outlook remains cautious due to weak technical momentum and lack of fundamental data. Investment opportunity hinges on dividend yield sustainability, but risks include absence of earnings visibility and bearish technical pressure. Key catalysts for reversal would require positive earnings surprises or upward analyst revisions, which are currently unavailable.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →